Table 1.

A collective description of the study group.

No.	Sex	Age (yr)	Comorbidities	CP Anti-SARS-CoV-2 Titer	Symptoms Onset to Admission (Days)	Admission to Transfusion (Days)	Length of Hospital Stay (Days)	Negative PCR (Days after Transfusion)	Anti-Inflammatory Treatment	Chest X-ray	Disease Severity (Oxygen Demand), Outcome
1	F	6	aplastic anaemia	1:600	3	37	59	3	DEX 0.3 mg/kg/24h	normal	Mo, T*
2	F	17	ADEM	1:1850	2	10	20	11	MPRED 30 mg/kg/24h	normal	Mo, R&D
3	M	14	CKD. KTx	1:600	2	12	20	6	PRED 0.1 mg/kg/24h	normal	Mo, R&D
4	M	12	CP. epilepsy. Chiari malformation	1:250	5	18	35	8	DEX 0.15 mg/kg/24h	parenchymal consolidations	S (FiO2 max 0.4), R&D
5	M	17	CP. epilepsy	1:650	5	7	31	8	DEX 0.15 mg/kg/24h	parenchymal consolidations	S (FiO2 max. 0.8), R&D
6	F	16	anorexia nervosa	1:600			33	3		normal	Mi, R&D
7	F	11	nephrotic syndrome	1:700	0	5	17	11	PRED 1.7 mg/kg/24h	normal	Mo, R&D
8	M	15	non-compaction cardiomyopathy	1:1700	2	6	9	3	DEX 0.15 mg/kg/24h	parenchymal consolidations	Mo (face mask O2 flow 6 L/min), R&D
9	M	8	suspected lymphoma	1:650	5	6	8	3		enlarged mediastinal shadow	Mo, R&D
10	F	6/12	thermal burn	1:700			8	3		peribronchial consolidations	Mi, R&D
11	F	1	sepsis. HUS	1:1600	2	3	22	3		parenchymal consolidations	S (FiO2 max 0.35), R&D
12	M	17	FA. DCM	1:600	7	10	17	11	DEX 0.15 mg/kg/24h	parenchymal consolidations	Mo (face mask O2 flow 7 L/min), R&D
13	F	5/12	renal agenesis. vesicostomy. VSD	1:550	0	3	15	30		normal	Mo, R&D

CP—convalescent plasma, PCR—polymerase chain reaction, ADEM—acute disseminated encephalomyelitis, CKD—chronic kidney disease, KTx—kidney transplant, CP—cerebral palsy, HUS—hemolytic uremic syndrome, FA—Friedreich’s ataxia, DCM—dilated cardiomyopathy, VSD—ventricular septal defect, PRED—prednisolone, MPRED—methylprednisolone, DEX—dexamethasone, Mi—mild, Mo—moderate, S—severe, R&D—recovered and discharged, T*—transferred to another hospital (patient required hematopoietic stem cell transplantation).